


SUPPLEMENTARY FIGURES



Supplementary Figure 1. CSN-B decrease proinflammatory genes by increasing Nur77 in MPP+-treated PC12 cells. MPP⁺ incubation pronouncedly increased level of NF-κB, TNF- α , IL-6 and MCP-1, while this elevation was abolished by CSN-B, the treatment of siNur77 increased this effect. (A) Effects of NF-κB, TNF- α , MCP-1, IL-6 on cytokines expression in MPP⁺, CSN-B and siNur77 treated PC12 cells. (B–E) Quantitative analysis of protein expression of NF-κB, TNF- α , MCP-1, IL-6. Results are expressed as the relative expression of β-actin (*** P<0.001 compared with control group; *### P<0.001, **P<0.005, compared with MMP⁺ group; *NS means not significant; n=3, mean +/- SEM).



Supplementary Figure 2. CSN-B enhance oxidant stress by increasing Nur77 in MPP+-treated PC12 cells. CSN-B treatment significantly increase the level of Nrf2,HO-1 and NQO-1compared to MPP $^{+}$ group, Silencing of Nur77 with siRNA significantly reduced the expression of Nrf2, HO-1 and NQO-1 under MPP $^{+}$ stress. After Silencing of Nur77 with siRNA, CSN-B incubation couldn't significantly increase the protein expression of Nrf2, HO-1 and NQO-1. (A) Effects of Nrf2, HO-1, NQO-1 on cytokines expression in MPP $^{+}$, CSN-B and siNur77 treated PC12 cells. (B–D) Quantitative analysis of protein expression of Nrf2, HO-1, NQO-1. Results are expressed as the relative expression of β-actin. (**P<0.05 compared with control group; **P<0.05 compared with MMPP $^{+}$ group; n=3, mean+/- SEM).



Supplementary Figure 3. Silencing efficiency detection of siNur77. (A) Silence effect of siNur77 in PC12 cells. Phase contrast shown all PC12 cells, fluorescence indicate PC12 cells after silencing Nur77. (B) Effects of Nur77 on cytokines expression in siRNA treated PC12 cells. (C) Quantitative analysis of protein expression of Nur77. Results are expressed as the relative expression of β -actin. Data are expressed as mean \pm SEM; **p< 0.01versus control group, **p< 0.01versus scrambled siRNA treatment group.